Efficacy of tight control of Infliximab (IFX) for Crohn's disease (CD) by CRP value and fecal concentration of calprotectin (Quattro C study)
Not Applicable
Recruiting
- Conditions
- Crohn's disease
- Registration Number
- JPRN-UMIN000011820
- Lead Sponsor
- ationalOrganizationHospital Fukuyama medical center
- Brief Summary
under analysis
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Patients receiving IFX with 10 mg/kg dose Patients receiving IFX at interval of less than 6 weeks
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical remission rate after 104 weeks (Interim analysis performed in 52 weeks)
- Secondary Outcome Measures
Name Time Method Correlation with change of IFX dose and CRP value or fecal concentration of calprotectin